EMAK S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.08 EUR | -1.64% |
|
+1.89% | -1.64% |
| Mar. 19 | Bioera tops post-accounts; goes down Restart | AN |
| Mar. 15 | Giuliano Ferrari buys 20,000 shares in Emak | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 149.1 | 179.6 | 345.9 | 189.9 | 178.8 | 175.9 | - | - |
| Enterprise Value (EV) 1 | 149.1 | 307.4 | 490.2 | 367.2 | 178.8 | 365.9 | 349.9 | 332.9 |
| P/E ratio | 11.5 x | 9.31 x | 10.6 x | 6.3 x | 9.38 x | 6.71 x | 5.68 x | 4.93 x |
| Yield | - | 4.1% | 3.55% | 5.57% | - | 5.93% | 7.04% | - |
| Capitalization / Revenue | - | 0.38 x | 0.59 x | 0.31 x | 0.32 x | 0.28 x | 0.27 x | 0.26 x |
| EV / Revenue | - | 0.65 x | 0.83 x | 0.61 x | 0.32 x | 0.59 x | 0.54 x | 0.49 x |
| EV / EBITDA | - | 5.46 x | 6.33 x | 4.79 x | 2.63 x | 4.69 x | 4.17 x | 3.7 x |
| EV / FCF | - | 10.7 x | 39.2 x | -47.8 x | - | 15.2 x | 13.5 x | 11.1 x |
| FCF Yield | - | 9.37% | 2.55% | -2.09% | - | 6.56% | 7.43% | 9.01% |
| Price to Book | - | 0.82 x | 1.36 x | 0.7 x | - | 0.59 x | 0.55 x | 0.52 x |
| Nbr of stocks (in thousands) | 163,538 | 163,538 | 163,538 | 162,838 | 162,838 | 162,838 | - | - |
| Reference price 2 | 0.9120 | 1.098 | 2.115 | 1.166 | 1.098 | 1.080 | 1.080 | 1.080 |
| Announcement Date | 3/30/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 469.8 | 588.3 | 605.7 | 566.3 | 623 | 648 | 674 |
| EBITDA 1 | - | 56.3 | 77.44 | 76.64 | 67.88 | 78 | 84 | 90 |
| EBIT 1 | - | 32.94 | 52.9 | 46.76 | 37.22 | 49 | 55 | 60 |
| Operating Margin | - | 7.01% | 8.99% | 7.72% | 6.57% | 7.87% | 8.49% | 8.9% |
| Earnings before Tax (EBT) 1 | - | 22.81 | 45.88 | 44.1 | 25.44 | 37.8 | 44.5 | 51.1 |
| Net income 1 | 12.95 | 19.3 | 32.51 | 30.27 | 19.08 | 26 | 31 | 36 |
| Net margin | - | 4.11% | 5.53% | 5% | 3.37% | 4.17% | 4.78% | 5.34% |
| EPS 2 | 0.0790 | 0.1180 | 0.1990 | 0.1850 | 0.1170 | 0.1610 | 0.1900 | 0.2190 |
| Free Cash Flow 1 | - | 28.81 | 12.52 | -7.683 | - | 24 | 26 | 30 |
| FCF margin | - | 6.13% | 2.13% | -1.27% | - | 3.85% | 4.01% | 4.45% |
| FCF Conversion (EBITDA) | - | 51.17% | 16.16% | - | - | 30.77% | 30.95% | 33.33% |
| FCF Conversion (Net income) | - | 149.26% | 38.5% | - | - | 92.31% | 83.87% | 83.33% |
| Dividend per Share 2 | - | 0.0450 | 0.0750 | 0.0650 | - | 0.0640 | 0.0760 | - |
| Announcement Date | 3/30/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 S1 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | 116.4 |
| EBITDA | - | - | - | - |
| EBIT 1 | - | - | - | -1.1 |
| Operating Margin | - | - | - | -0.95% |
| Earnings before Tax (EBT) 1 | - | - | - | -4.966 |
| Net income 1 | 11.13 | 21.52 | 0.542 | -2.992 |
| Net margin | - | - | - | -2.57% |
| EPS | 0.0680 | 0.1320 | 0.003000 | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 5/15/23 | 8/9/23 | 11/14/23 | 3/14/24 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 128 | 144 | 177 | - | 190 | 174 | 157 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 2.271 x | 1.863 x | 2.313 x | - | 2.436 x | 2.071 x | 1.744 x |
| Free Cash Flow 1 | - | 28.8 | 12.5 | -7.68 | - | 24 | 26 | 30 |
| ROE (net income / shareholders' equity) | - | 8.98% | 13.7% | 11.5% | - | 9.2% | 10.2% | 11% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 1.350 | 1.550 | 1.680 | - | 1.820 | 1.950 | 2.090 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 14.1 | 17 | 21.4 | - | 22 | 22 | 22 |
| Capex / Sales | - | 3.01% | 2.9% | 3.52% | - | 3.53% | 3.4% | 3.26% |
| Announcement Date | 3/30/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.08
EUR
Average target price
1.85
EUR
Spread / Average Target
+71.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.64% | 188M | |
| -1.64% | 109B | |
| -8.84% | 9.14B | |
| +10.34% | 4.35B | |
| +27.11% | 2.79B | |
| +64.52% | 2.27B | |
| -10.00% | 1.28B | |
| +18.94% | 834M | |
| +102.98% | 603M | |
| +39.37% | 546M |
- Stock Market
- Equities
- EM Stock
- Financials Emak S.p.A.
